Zofran is a 5-ht3 receptor antagonist indicated for the prevention of:
Nausea and vomiting associated with highly emetogenic cancer chemotherapy, including cisplatin greater than or equal to 50 mg/m2
Nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy
Nausea and vomiting associated with radiotherapy in patients receiving either total body irradiation, single high-dose fraction to the abdomen, or daily fractions to the abdomen
Postoperative nausea and/or vomiting
Disclaimer: CTX Lifesciences respects patent laws and conventions of pharmaceuticals as applicable in different countries.
API/Substances covered by patent are not offered to the countries where the patent law is in force. However, the final responsibility lies with the customer.